Journal
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
Volume 32, Issue 3, Pages 278-283Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MNH.0000000000000877
Keywords
antineutrophil cytoplasmic antibody-associated vasculitis; avacopan; glucocorticoids; plasma exchange; rituximab
Categories
Ask authors/readers for more resources
The review discusses recent advancements in the treatment of antineutrophil cytoplasmic antibody associated vasculitis (AAV), including the use of targeted plasma exchange, increased use of rituximab, and lower glucocorticoid dosing. However, striking a balance between relapse morbidity and immunosuppression toxicities remains challenging.
Purpose of reviewAntineutrophil cytoplasmic antibody associated vasculitis (AAV) is a group of autoimmune disorders of small blood vessels. While outcomes in AAV have improved with the use of glucocorticoids (GC) and other immunosuppressants, these treatments are associated with significant toxicities. Infections are the major cause of mortality within the first year of treatment. There is a move towards newer treatments with better safety profiles. This review reflects on recent advances in the treatment of AAV.Recent findingsThe role of plasma exchange (PLEX) in AAV with kidney involvement has been clarified with new BMJ guideline recommendations following the publication of PEXIVAS and an updated meta-analysis. Lower dose GC regimens are now standard of care. Avacopan (C5a receptor antagonist) was noninferior to a regimen of GC therapy and is a potential steroid-sparing agent. Lastly, rituximab-based regimens were noninferior to cyclophosphamide in two trials for induction of remission and superior to azathioprine in one trial of maintenance of remission.AAV treatments have changed tremendously over the past decade with a drive towards targeted PLEX use, increased rituximab use and lower GC dosing. Striking a crucial balance between morbidity from relapses and toxicities from immunosuppression remains a challenging path to navigate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available